Genmab

GMAB

Market cap $20.9B

Danish drugmaker Genmab and its U.S. partner AbbVie said on Friday that their drug for a type of blood cancer failed to improve the survival rate in patients in a late-stage study.

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])* in patients treated with epcoritamab monotherapy. Additionally, improvements were observed in the complete response rate, duration of response, and time to next treatment.

Company Announcement Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps COPENHAGEN, Denmark; January 16, 2026 – Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])* in patients treated with epcoritamab monotherapy. Additionally, improvements were observed in the complete response rate, duration of response, and time to next treatment among patients treated with epcoritamab monotherapy.

Genmab A/S (GMAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Genmab is transitioning from a royalty-driven licensor to an innovation powerhouse with a robust, proprietary pipeline. GMAB delivered 21% revenue growth and 52% operating profit growth, supported by $3.4B in cash and strong operating leverage. Epkinly and Rina-S, with positive clinical data and full or majority ownership, underpin GMAB's multi-billion dollar peak sales potential.

Media Release COPENHAGEN, Denmark; January 07, 2026 Supports Genmab's ambition to build an AI-enabled innovation model that advances the company's vision of bringing transformative antibody medicines to patients Genmab A/S (Nasdaq: GMAB ) a nnounced today a partnership with Anthropic to advance and enhance the company's r esearch and d evelopment (R&D) processes through the adoption of cutting-edge artificial intelligence (AI) capabilities . Under the agreement, Genmab and Anthropic will design and deploy custom, Claude-powered agentic AI solutions to support Genmab's clinical development priorities.

COPENHAGEN, Denmark--(BUSINESS WIRE)-- #AI--Genmab has partnered with Anthropic to advance its research and development (R&D) processes through the adoption of agentic AI capabilities.

Media Release COPENHAGEN, Denmark; January 5, 2026 Genmab A/S  (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 44 th  Annual J.P. Morgan Healthcare Conference in San Francisco at 3:45 PM PST / 6: 45 PM EST on January 1 3 , 202 6 , 12: 45  AM CET on January 1 4 , 202 6 . The live and archived webcast of the presentation will be available on Genmab's website at https://ir.genmab.com/events-presentations.

Genmab A/S (NASDAQ: GMAB) on Monday said it will discontinue further clinical development of acasunlimab.

Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish drugmaker said on Monday.